Baxter (NYSE:BAX)
(BAX shares –6.7% since Feb. 19)
“Our medically essential products put us on the front lines of this pandemic, and our 50,000 colleagues are rising to the challenge to make a meaningful difference for patients. Given that demand is at extraordinary levels, it is critical that we prioritize getting our products where they are most needed – hospitals that are being overwhelmed by an influx of patients who are critically ill from COVID-19.”
– José (Joe) E. Almeida, CEO of Baxter